ConductScience.org, home

Trial · NCT01263483

Results by group51

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Change From Baseline in Glycosylated Hemoglobin (Week 12).Voglibose 0.2 mg TID0.04Standard Deviation 0.457percentage of Glycosylated Hemoglobin
Change From Baseline in Glycosylated Hemoglobin (Week 12).Alogliptin 12.5 mg QD-0.96Standard Deviation 0.553percentage of Glycosylated Hemoglobin
Change From Baseline in Glycosylated Hemoglobin (Week 12).Alogliptin 25 mg QD and Voglibose 0.2 mg TID-0.91Standard Deviation 0.485percentage of Glycosylated Hemoglobin
Change From Baseline in Glycosylated Hemoglobin (Week 2).Voglibose 0.2 mg TID-0.01Standard Deviation 0.180percentage of Glycosylated Hemoglobin
Change From Baseline in Glycosylated Hemoglobin (Week 2).Alogliptin 12.5 mg QD-0.19Standard Deviation 0.149percentage of Glycosylated Hemoglobin
Change From Baseline in Glycosylated Hemoglobin (Week 2).Alogliptin 25 mg QD and Voglibose 0.2 mg TID-0.21Standard Deviation 0.175percentage of Glycosylated Hemoglobin
Change From Baseline in Glycosylated Hemoglobin (Week 4).Voglibose 0.2 mg TID-0.02Standard Deviation 0.301percentage of Glycosylated Hemoglobin
Change From Baseline in Glycosylated Hemoglobin (Week 4).Alogliptin 12.5 mg QD-0.44Standard Deviation 0.234percentage of Glycosylated Hemoglobin
Change From Baseline in Glycosylated Hemoglobin (Week 4).Alogliptin 25 mg QD and Voglibose 0.2 mg TID-0.43Standard Deviation 0.263percentage of Glycosylated Hemoglobin
Change From Baseline in Glycosylated Hemoglobin (Week 8).Voglibose 0.2 mg TID-0.01Standard Deviation 0.398percentage of Glycosylated Hemoglobin
Change From Baseline in Glycosylated Hemoglobin (Week 8).Alogliptin 12.5 mg QD-0.74Standard Deviation 0.427percentage of Glycosylated Hemoglobin
Change From Baseline in Glycosylated Hemoglobin (Week 8).Alogliptin 25 mg QD and Voglibose 0.2 mg TID-0.75Standard Deviation 0.392percentage of Glycosylated Hemoglobin
Change From Baseline in Fasting Plasma Glucose (Week 2).Voglibose 0.2 mg TID-3.5Standard Deviation 21.28mg/dL
Change From Baseline in Fasting Plasma Glucose (Week 2).Alogliptin 12.5 mg QD-15.5Standard Deviation 18.77mg/dL
Change From Baseline in Fasting Plasma Glucose (Week 2).Alogliptin 25 mg QD and Voglibose 0.2 mg TID-18.8Standard Deviation 19.89mg/dL
Change From Baseline in Fasting Plasma Glucose (Week 4).Voglibose 0.2 mg TID-0.6Standard Deviation 23.71mg/dL
Change From Baseline in Fasting Plasma Glucose (Week 4).Alogliptin 12.5 mg QD-16.2Standard Deviation 21.84mg/dL
Change From Baseline in Fasting Plasma Glucose (Week 4).Alogliptin 25 mg QD and Voglibose 0.2 mg TID-22.6Standard Deviation 23.96mg/dL
Change From Baseline in Fasting Plasma Glucose (Week 8).Voglibose 0.2 mg TID-2.5Standard Deviation 25.94mg/dL
Change From Baseline in Fasting Plasma Glucose (Week 8).Alogliptin 12.5 mg QD-20.8Standard Deviation 22.10mg/dL

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01263483/results